Neuroprogression: the hidden mechanism of depression

Código QR

Neuroprogression: the hidden mechanism of depression

Norma A Labra Ruiz,1 Daniel Santamaría del Ángel,1 Hugo Juárez Olguín,2 Miroslava Lindoro Silva2 1Laboratory of Neurosciences, Instituto Nacional de Pediatria (INP), Mexico City, Mexico; 2Laboratory of Pharmacology, Instituto Nacional de Pediatr&iacute...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Labra Ruiz NA, Santamaría del Ángel D, Juárez Olguín H, Lindoro Silva M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Depressive disorder monoamines neuroprogression neuroendocrine Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/50a8c775823a4144a3092eeffc86a539
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ketamine in Bipolar Disorder: A Review
por: Wilkowska A, et al.
Publicado: (2020)

The noradrenergic paradox: implications in the management of depression and anxiety
por: Montoya A, et al.
Publicado: (2016)

Depressed mood induction in early cigarette withdrawal is unaffected by acute monoamine precursor supplementation
por: Dowlati Y, et al.
Publicado: (2019)

Overcoming barriers to effective management of tardive dyskinesia
por: Caroff SN
Publicado: (2019)

APRESS: Apical Regulatory Super System, Serotonin, and Dopamine Interaction [Retraction]
por: Hinz M, et al.
Publicado: (2020)

APRESS: Apical Regulatory Super System, Serotonin and Dopamine Interaction [Expression of Concern]
por: Hinz M, et al.
Publicado: (2020)

A Retrospective Study of the Effects of Psychotropic Drugs on Neuroendocrine Hormones in Patients with Bipolar Disorder
por: Zhao S, et al.
Publicado: (2021)

Management of Treatment-Resistant Depression: Challenges and Strategies
por: Voineskos D, et al.
Publicado: (2020)

Validity of the Shahin Mixed Depression Scale: A Self-Rated Instrument Designed to Measure the Non-DSM Mixed Features in Depression
por: Shahin I, et al.
Publicado: (2020)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
por: Hammer-Helmich L, et al.
Publicado: (2018)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
por: Inoue T, et al.
Publicado: (2020)

Victimization In Childhood Affects Depression In Adulthood Via Neuroticism: A Path Analysis Study
por: Tachi S, et al.
Publicado: (2019)

Cognitive impairment in depression: recent advances and novel treatments
por: Perini G, et al.
Publicado: (2019)

Taiwanese Depression Questionnaire and AD8 Questionnaire for Screening Late-Life Depression in Communities
por: Wei YC, et al.
Publicado: (2021)

Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016)

Gene expression-based biological test for major depressive disorder: an advanced study
por: Watanabe S, et al.
Publicado: (2017)

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression
por: Szarmach J, et al.
Publicado: (2020)

Atypical depression: current perspectives
por: Łojko D, et al.
Publicado: (2017)

Pathogenic beliefs among patients with depressive disorders
por: Neelapaijit A, et al.
Publicado: (2017)

Depression and pain: testing of serial multiple mediators
por: Wongpakaran T, et al.
Publicado: (2016)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study
por: Wang G, et al.
Publicado: (2016)

Self-stigma and quality of life in patients with depressive disorder: a cross-sectional study
por: Holubova M, et al.
Publicado: (2016)

Psychometric Properties of the Chinese Version of the Bipolar Depression Rating Scale for Bipolar Disorder
por: Chen JX, et al.
Publicado: (2021)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
por: Tomita T, et al.
Publicado: (2016)

Sex differences in gut microbiota in patients with major depressive disorder
por: Chen JJ, et al.
Publicado: (2018)

Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
por: Zhang L, et al.
Publicado: (2018)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada E, et al.
Publicado: (2017)

Validity and test–retest reliability of the Persian version of the Montgomery–Asberg Depression Rating Scale
por: Ahmadpanah M, et al.
Publicado: (2016)

Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder
por: Bo Q, et al.
Publicado: (2019)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
por: McIntyre RS, et al.
Publicado: (2021)

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
por: Li G, et al.
Publicado: (2016)

Quality of life and coping strategies of outpatients with a depressive disorder in maintenance therapy – a cross-sectional study
por: Holubova M, et al.
Publicado: (2017)

Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
por: Askalsky P, et al.
Publicado: (2019)

Prevalence of Asymptomatic Venous Thromboembolism in Depressive Inpatients
por: Takeshima M, et al.
Publicado: (2020)

5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients
por: Dong ZQ, et al.
Publicado: (2016)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura R, et al.
Publicado: (2017)

Biomarkers for depression: recent insights, current challenges and future prospects
por: Strawbridge R, et al.
Publicado: (2017)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
por: Saragoussi D, et al.
Publicado: (2018)

Assessment of current clinical practices for major depression in Japan using a web-based questionnaire
por: Hori H, et al.
Publicado: (2019)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada E, et al.
Publicado: (2016)